Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 19 de 19
Filtrar
1.
Nature ; 591(7851): 645-651, 2021 03.
Artículo en Inglés | MEDLINE | ID: mdl-33589820

RESUMEN

Regulatory T (Treg) cells, although vital for immune homeostasis, also represent a major barrier to anti-cancer immunity, as the tumour microenvironment (TME) promotes the recruitment, differentiation and activity of these cells1,2. Tumour cells show deregulated metabolism, leading to a metabolite-depleted, hypoxic and acidic TME3, which places infiltrating effector T cells in competition with the tumour for metabolites and impairs their function4-6. At the same time, Treg cells maintain a strong suppression of effector T cells within the TME7,8. As previous studies suggested that Treg cells possess a distinct metabolic profile from effector T cells9-11, we hypothesized that the altered metabolic landscape of the TME and increased activity of intratumoral Treg cells are linked. Here we show that Treg cells display broad heterogeneity in their metabolism of glucose within normal and transformed tissues, and can engage an alternative metabolic pathway to maintain suppressive function and proliferation. Glucose uptake correlates with poorer suppressive function and long-term instability, and high-glucose conditions impair the function and stability of Treg cells in vitro. Treg cells instead upregulate pathways involved in the metabolism of the glycolytic by-product lactic acid. Treg cells withstand high-lactate conditions, and treatment with lactate prevents the destabilizing effects of high-glucose conditions, generating intermediates necessary for proliferation. Deletion of MCT1-a lactate transporter-in Treg cells reveals that lactate uptake is dispensable for the function of peripheral Treg cells but required intratumorally, resulting in slowed tumour growth and an increased response to immunotherapy. Thus, Treg cells are metabolically flexible: they can use 'alternative' metabolites in the TME to maintain their suppressive identity. Further, our results suggest that tumours avoid destruction by not only depriving effector T cells of nutrients, but also metabolically supporting regulatory populations.


Asunto(s)
Ácido Láctico/metabolismo , Linfocitos Infiltrantes de Tumor/metabolismo , Neoplasias/inmunología , Linfocitos T Reguladores/metabolismo , Animales , Línea Celular Tumoral , Proliferación Celular , Femenino , Glucosa/metabolismo , Humanos , Linfocitos Infiltrantes de Tumor/inmunología , Masculino , Ratones , Factores Supresores Inmunológicos/inmunología , Factores Supresores Inmunológicos/metabolismo , Linfocitos T Reguladores/inmunología
2.
Glia ; 68(1): 161-177, 2020 01.
Artículo en Inglés | MEDLINE | ID: mdl-31453649

RESUMEN

Schwann cell (SC)-specific monocarboxylate transporter 1 (MCT1) knockout mice were generated by mating MCT1 f/f mice with myelin protein zero (P0)-Cre mice. P0-Cre+/- , MCT1 f/f mice have no detectable early developmental defects, but develop hypomyelination and reduced conduction velocity in sensory, but not motor, peripheral nerves during maturation and aging. Furthermore, reduced mechanical sensitivity is evident in aged P0-Cre+/- , MCT1 f/f mice. MCT1 deletion in SCs impairs both their glycolytic and mitochondrial functions, leading to altered lipid metabolism of triacylglycerides, diacylglycerides, and sphingomyelin, decreased expression of myelin-associated glycoprotein, and increased expression of c-Jun and p75-neurotrophin receptor, suggesting a regression of SCs to a less mature developmental state. Taken together, our results define the contribution of SC MCT1 to both SC metabolism and peripheral nerve maturation and aging.


Asunto(s)
Envejecimiento/metabolismo , Transportadores de Ácidos Monocarboxílicos/metabolismo , Vaina de Mielina/metabolismo , Células de Schwann/metabolismo , Células Receptoras Sensoriales/metabolismo , Simportadores/metabolismo , Envejecimiento/genética , Animales , Células Cultivadas , Femenino , Masculino , Ratones , Ratones Noqueados , Ratones Transgénicos , Transportadores de Ácidos Monocarboxílicos/deficiencia , Transportadores de Ácidos Monocarboxílicos/genética , Vaina de Mielina/genética , Conducción Nerviosa/fisiología , Nervio Sural/metabolismo , Simportadores/deficiencia , Simportadores/genética
3.
Proc Natl Acad Sci U S A ; 113(47): E7580-E7589, 2016 11 22.
Artículo en Inglés | MEDLINE | ID: mdl-27834214

RESUMEN

Missense mutations in ubiquilin 2 (UBQLN2) cause ALS with frontotemporal dementia (ALS-FTD). Animal models of ALS are useful for understanding the mechanisms of pathogenesis and for preclinical investigations. However, previous rodent models carrying UBQLN2 mutations failed to manifest any sign of motor neuron disease. Here, we show that lines of mice expressing either the ALS-FTD-linked P497S or P506T UBQLN2 mutations have cognitive deficits, shortened lifespans, and develop motor neuron disease, mimicking the human disease. Neuropathologic analysis of the mice with end-stage disease revealed the accumulation of ubiquitinated inclusions in the brain and spinal cord, astrocytosis, a reduction in the number of hippocampal neurons, and reduced staining of TAR-DNA binding protein 43 in the nucleus, with concomitant formation of ubiquitin+ inclusions in the cytoplasm of spinal motor neurons. Moreover, both lines displayed denervation muscle atrophy and age-dependent loss of motor neurons that correlated with a reduction in the number of large-caliber axons. By contrast, two mouse lines expressing WT UBQLN2 were mostly devoid of clinical and pathological signs of disease. These UBQLN2 mouse models provide valuable tools for identifying the mechanisms underlying ALS-FTD pathogenesis and for investigating therapeutic strategies to halt disease.


Asunto(s)
Proteínas Adaptadoras del Transporte Vesicular/genética , Esclerosis Amiotrófica Lateral/genética , Proteínas de Unión al ADN/metabolismo , Modelos Animales de Enfermedad , Demencia Frontotemporal/genética , Mutación Missense , Proteínas Adaptadoras Transductoras de Señales , Proteínas Adaptadoras del Transporte Vesicular/metabolismo , Esclerosis Amiotrófica Lateral/complicaciones , Esclerosis Amiotrófica Lateral/metabolismo , Animales , Proteínas Relacionadas con la Autofagia , Núcleo Celular/metabolismo , Citoplasma/metabolismo , Demencia Frontotemporal/etiología , Demencia Frontotemporal/metabolismo , Humanos , Cuerpos de Inclusión/metabolismo , Ratones , Neuronas Motoras/metabolismo , Ubiquitinación
4.
Nature ; 487(7408): 443-8, 2012 Jul 26.
Artículo en Inglés | MEDLINE | ID: mdl-22801498

RESUMEN

Oligodendroglia support axon survival and function through mechanisms independent of myelination, and their dysfunction leads to axon degeneration in several diseases. The cause of this degeneration has not been determined, but lack of energy metabolites such as glucose or lactate has been proposed. Lactate is transported exclusively by monocarboxylate transporters, and changes to these transporters alter lactate production and use. Here we show that the most abundant lactate transporter in the central nervous system, monocarboxylate transporter 1 (MCT1, also known as SLC16A1), is highly enriched within oligodendroglia and that disruption of this transporter produces axon damage and neuron loss in animal and cell culture models. In addition, this same transporter is reduced in patients with, and in mouse models of, amyotrophic lateral sclerosis, suggesting a role for oligodendroglial MCT1 in pathogenesis. The role of oligodendroglia in axon function and neuron survival has been elusive; this study defines a new fundamental mechanism by which oligodendroglia support neurons and axons.


Asunto(s)
Esclerosis Amiotrófica Lateral/metabolismo , Esclerosis Amiotrófica Lateral/patología , Axones/metabolismo , Transportadores de Ácidos Monocarboxílicos/metabolismo , Neuronas Motoras/patología , Degeneración Nerviosa/metabolismo , Oligodendroglía/metabolismo , Simportadores/metabolismo , Esclerosis Amiotrófica Lateral/genética , Animales , Axones/patología , Línea Celular , Supervivencia Celular , Modelos Animales de Enfermedad , Regulación hacia Abajo , Heterocigoto , Humanos , Ácido Láctico/metabolismo , Ratones , Ratones Transgénicos , Transportadores de Ácidos Monocarboxílicos/deficiencia , Transportadores de Ácidos Monocarboxílicos/genética , Neuronas Motoras/metabolismo , Vaina de Mielina/metabolismo , Transporte de Proteínas , ARN Interferente Pequeño , Superóxido Dismutasa/genética , Superóxido Dismutasa/metabolismo , Superóxido Dismutasa-1 , Simportadores/deficiencia , Simportadores/genética
5.
Semin Neurol ; 36(5): 409-418, 2016 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-27704495

RESUMEN

Neuromuscular diseases are a broadly defined group of disorders that all involve injury or dysfunction of peripheral nerves or muscle. The site of injury can be in the cell bodies (i.e., amyotrophic lateral sclerosis [ALS] or sensory ganglionopathies), axons (i.e., axonal peripheral neuropathies or brachial plexopathies), Schwann cells (i.e., chronic inflammatory demyelinating polyradiculoneuropathy), neuromuscular junction (i.e., myasthenia gravis or Lambert-Eaton myasthenic syndrome), muscle (i.e., inflammatory myopathy or muscular dystrophy), or any combination of these sites. Some neuromuscular diseases are also associated with central nervous system disease, such as ALS, but most are restricted to the peripheral nervous system. The multitude of possible sites of injury can make neuromuscular diseases difficult to diagnose. Here the author reviews key features of the clinical presentation that help localize the site of injury and some basic tenets of electromyography. He then shares several pearls in diagnosing and treating patients with specific neuromuscular diseases.


Asunto(s)
Enfermedades Neuromusculares , Esclerosis Amiotrófica Lateral , Electromiografía , Humanos , Síndrome Miasténico de Lambert-Eaton , Miastenia Gravis , Enfermedades Neuromusculares/diagnóstico , Enfermedades Neuromusculares/terapia
6.
Muscle Nerve ; 45(5): 755-61, 2012 May.
Artículo en Inglés | MEDLINE | ID: mdl-22499107

RESUMEN

INTRODUCTION: The diagnosis of amyloid myopathy is delayed when monoclonal gammopathies are not detected on initial testing and muscle biopsies are nondiagnostic, and the EMG and symptoms can mimic an inflammatory myopathy. METHODS: Case report of a patient presenting with severe progressive muscle weakness of unclear etiology despite an extensive workup including two nondiagnostic muscle biopsies. RESULTS: Directed by MRI, a third biopsy revealed amyloid angiopathy and noncongophilic kappa light chain deposition in scattered subsarcolemmal rings and perimysial regions. A serum free light chain (FLC) assay revealed a kappa monoclonal gammopathy, which was not detected by multiple immunofixations. CONCLUSIONS: The spectrum of immunoglobulin deposition in muscle is similar to other organs. It comprises a continuum that includes parenchymal amyloid deposition, amyloid angiopathy, and noncongophilic Light Chain Deposition Disease (LCDD). We recommend including the FLC assay in the routine investigation for monoclonal gammopathies. This case also highlights the value of MRI-guided muscle biopsy.


Asunto(s)
Cadenas Ligeras de Inmunoglobulina/sangre , Músculo Esquelético/metabolismo , Paraproteinemias/sangre , Paraproteinemias/patología , Adenosina Trifosfatasas/metabolismo , Anciano , Amiloidosis/sangre , Amiloidosis/etiología , Biopsia , Rojo Congo , Humanos , Cadenas kappa de Inmunoglobulina/metabolismo , Masculino , Músculo Esquelético/patología , Paraproteinemias/complicaciones
7.
Neurotherapeutics ; 18(4): 2185-2199, 2021 10.
Artículo en Inglés | MEDLINE | ID: mdl-34773210

RESUMEN

Cellular metabolism is critical not only for cell survival, but also for cell fate, function, and intercellular communication. There are several different metabolic transporters expressed in the peripheral nervous system, and they each play important roles in maintaining cellular energy. The major source of energy in the peripheral nervous system is glucose, and glucose transporters 1 and 3 are expressed and allow blood glucose to be imported and utilized by peripheral nerves. There is also increasing evidence that other sources of energy, particularly monocarboxylates such as lactate that are transported primarily by monocarboxylate transporters 1 and 2 in peripheral nerves, can be efficiently utilized by peripheral nerves. Finally, emerging evidence supports an important role for connexins and possibly pannexins in the supply and regulation of metabolic energy. In this review, we will first define these critical metabolic transporter subtypes and then examine their localization in the peripheral nervous system. We will subsequently discuss the evidence, which comes both from experiments in animal models and observations from human diseases, supporting critical roles played by these metabolic transporters in the peripheral nervous system. Despite progress made in understanding the function of these transporters, many questions and some discrepancies remain, and these will also be addressed throughout this review. Peripheral nerve metabolism is fundamentally important and renewed interest in these pathways should help to answer many of these questions and potentially provide new treatments for neurologic diseases that are partly, or completely, caused by disruption of metabolism.


Asunto(s)
Transportadores de Ácidos Monocarboxílicos , Enfermedades del Sistema Nervioso , Animales , Glucosa/metabolismo , Ácido Láctico/metabolismo , Transportadores de Ácidos Monocarboxílicos/metabolismo , Nervios Periféricos/metabolismo
8.
Cell Rep ; 34(2): 108610, 2021 01 12.
Artículo en Inglés | MEDLINE | ID: mdl-33440165

RESUMEN

Oligodendrocytes (OLs) are important for myelination and shuttling energy metabolites lactate and pyruvate toward axons through their expression of monocarboxylate transporter 1 (MCT1). Recent studies suggest that loss of OL MCT1 causes axonal degeneration. However, it is unknown how widespread and chronic loss of MCT1 in OLs specifically affects neuronal energy homeostasis with aging. To answer this, MCT1 conditional null mice were generated that allow for OL-specific MCT1 ablation. We observe that MCT1 loss from OL lineage cells is dispensable for normal myelination and axonal energy homeostasis early in life. By contrast, loss of OL lineage MCT1 expression with aging leads to significant axonal degeneration with concomitant hypomyelination. These data support the hypothesis that MCT1 is important for neuronal energy homeostasis in the aging central nervous system (CNS). The reduction in OL MCT1 that occurs with aging may enhance the risk for axonal degeneration and atrophy in neurodegenerative diseases.


Asunto(s)
Axones/metabolismo , Transportadores de Ácidos Monocarboxílicos/metabolismo , Vaina de Mielina/metabolismo , Degeneración Nerviosa/metabolismo , Oligodendroglía/metabolismo , Simportadores/metabolismo , Animales , Femenino , Masculino , Ratones , Ratones Transgénicos , Transportadores de Ácidos Monocarboxílicos/deficiencia , Vaina de Mielina/patología , Oligodendroglía/patología , Simportadores/deficiencia
9.
J Clin Invest ; 131(21)2021 11 01.
Artículo en Inglés | MEDLINE | ID: mdl-34491913

RESUMEN

Peripheral nerves have the capacity for regeneration, but the rate of regeneration is so slow that many nerve injuries lead to incomplete recovery and permanent disability for patients. Macrophages play a critical role in the peripheral nerve response to injury, contributing to both Wallerian degeneration and nerve regeneration, and their function has recently been shown to be dependent on intracellular metabolism. To date, the impact of their intracellular metabolism on peripheral nerve regeneration has not been studied. We examined conditional transgenic mice with selective ablation in macrophages of solute carrier family 16, member 1 (Slc16a1), which encodes monocarboxylate transporter 1 (MCT1), and found that MCT1 contributed to macrophage metabolism, phenotype, and function, specifically in regard to phagocytosis and peripheral nerve regeneration. Adoptive cell transfer of wild-type macrophages ameliorated the impaired nerve regeneration in macrophage-selective MCT1-null mice. We also developed a mouse model that overexpressed MCT1 in macrophages and found that peripheral nerves in these mice regenerated more rapidly than in control mice. Our study provides further evidence that MCT1 has an important biological role in macrophages and that manipulations of macrophage metabolism can enhance recovery from peripheral nerve injuries, for which there are currently no approved medical therapies.


Asunto(s)
Macrófagos/metabolismo , Transportadores de Ácidos Monocarboxílicos/metabolismo , Regeneración Nerviosa , Traumatismos de los Nervios Periféricos/metabolismo , Nervio Ciático , Simportadores/metabolismo , Animales , Femenino , Masculino , Ratones , Ratones Transgénicos , Transportadores de Ácidos Monocarboxílicos/genética , Traumatismos de los Nervios Periféricos/genética , Nervio Ciático/lesiones , Nervio Ciático/fisiología , Simportadores/genética
10.
Cell Metab ; 32(5): 695-696, 2020 11 03.
Artículo en Inglés | MEDLINE | ID: mdl-33147480

RESUMEN

Glia-neuron interactions underlie a number of homeostatic processes in the brain. In this issue of Cell Metabolism, Li et al. (2020) demonstrate that the regeneration of central nervous system axons is accelerated through modulation of neuronal GABA-B receptor activity by metabolic energy intermediaries released from glia.


Asunto(s)
Axones , Regeneración Nerviosa , Sistema Nervioso Central , Neuroglía , Neuronas
11.
Front Cell Neurosci ; 14: 589582, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-33132853

RESUMEN

Research over the last couple of decades has provided novel insights into lactate neurobiology and the implications of lactate transport-driven neuroenergetics in health and diseases of peripheral nerve and the brain. The expression pattern of lactate transporters in glia and neurons has now been described, though notable controversies and discrepancies remain. Importantly, down- and up-regulation experiments are underway to better understand the function of these transporters in different systems. Lactate transporters in peripheral nerves are important for maintenance of axon and myelin integrity, motor end-plate integrity, the development of diabetic peripheral neuropathy (DPN), and the functional recovery following nerve injuries. Similarly, brain energy metabolism and functions ranging from development to synaptic plasticity to axonal integrity are also dependent on lactate transport primarily between glia and neurons. This review is focused on critically analysing the expression pattern and the functions of lactate transporters in peripheral nerves and the brain and highlighting their role in glia-neuron metabolic crosstalk in physiological and pathological conditions.

12.
Exp Neurol ; 333: 113415, 2020 11.
Artículo en Inglés | MEDLINE | ID: mdl-32717355

RESUMEN

Diabetic peripheral neuropathy (DPN) is one of the most common complications in diabetic patients. Though the exact mechanism for DPN is unknown, it clearly involves metabolic dysfunction and energy failure in multiple cells within the peripheral nervous system. Lactate is an alternate source of metabolic energy that is increasingly recognized for its role in supporting neurons. The primary transporter for lactate in the nervous system, monocarboxylate transporter-1 (MCT1), has been shown to be critical for peripheral nerve regeneration and metabolic support to neurons/axons. In this study, MCT1 was reduced in both sciatic nerve and dorsal root ganglia in wild-type mice treated with streptozotocin (STZ), a common model of type-1 diabetes. Heterozygous MCT1 null mice that developed hyperglycemia following STZ treatment developed a more severe DPN compared to wild-type mice, as measured by greater axonal demyelination, decreased peripheral nerve function, and increased numbness to innocuous low-threshold mechanical stimulation. Given that MCT1 inhibitors are being developed as both immunosuppressive and chemotherapeutic medications, our results suggest that clinical development in patients with diabetes should proceed with caution. Collectively, our findings uncover an important role for MCT1 in DPN and provide a potential lead toward developing novel treatments for this currently untreatable disease.


Asunto(s)
Neuropatías Diabéticas/patología , Transportadores de Ácidos Monocarboxílicos/metabolismo , Simportadores/metabolismo , Animales , Axones/patología , Conducta Animal , Enfermedades Desmielinizantes/patología , Diabetes Mellitus Experimental/patología , Neuropatías Diabéticas/psicología , Ganglios Espinales/metabolismo , Ganglios Espinales/patología , Hipoestesia/genética , Ácido Láctico/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Transportadores de Ácidos Monocarboxílicos/genética , Conducción Nerviosa/efectos de los fármacos , Nervio Ciático/metabolismo , Nervio Ciático/patología , Simportadores/genética
13.
Neuron ; 108(4): 775-783.e4, 2020 11 25.
Artículo en Inglés | MEDLINE | ID: mdl-33022228

RESUMEN

A hexanucleotide repeat expansion at C9ORF72 is the most common genetic cause of amyotrophic lateral sclerosis (ALS)/frontotemporal dementia (FTD). Initial studies of bacterial artificial chromosome (BAC) transgenic mice harboring this expansion described an absence of motor and survival phenotypes. However, a recent study by Liu and colleagues described transgenic mice harboring a large repeat expansion (C9-500) and reported decreased survival and progressive motor phenotypes. To determine the utility of the C9-500 animals for understanding degenerative mechanisms, we validated and established two independent colonies of transgene carriers. However, extended studies of these animals for up to 1 year revealed no reproducible abnormalities in survival, motor function, or neurodegeneration. Here, we propose several potential explanations for the disparate nature of our findings from those of Liu and colleagues. Resolving the discrepancies we identify will be essential to settle the translational utility of C9-500 mice. This Matters Arising paper is in response to Liu et al. (2016), published in Neuron. See also the response by Nguyen et al. (2020), published in this issue.


Asunto(s)
Esclerosis Amiotrófica Lateral/fisiopatología , Proteína C9orf72/fisiología , Destreza Motora/fisiología , Degeneración Nerviosa/fisiopatología , Sobrevida/fisiología , Esclerosis Amiotrófica Lateral/genética , Animales , Proteína C9orf72/genética , Expansión de las Repeticiones de ADN/genética , Modelos Animales de Enfermedad , Heterocigoto , Masculino , Ratones , Ratones Transgénicos , Fenotipo
14.
Exp Neurol ; 309: 23-31, 2018 11.
Artículo en Inglés | MEDLINE | ID: mdl-30044944

RESUMEN

The brain is, by weight, only 2% the volume of the body and yet it consumes about 20% of the total glucose, suggesting that the energy requirements of the brain are high and that glucose is the primary energy source for the nervous system. Due to this dependence on glucose, brain physiology critically depends on the tight regulation of glucose transport and its metabolism. Glucose transporters ensure efficient glucose uptake by neural cells and contribute to the physiology and pathology of the nervous system. Despite this, a growing body of evidence demonstrates that for the maintenance of several neuronal functions, lactate, rather than glucose, is the preferred energy metabolite in the nervous system. Monocarboxylate transporters play a crucial role in providing metabolic support to axons by functioning as the principal transporters for lactate in the nervous system. Monocarboxylate transporters are also critical for axonal myelination and regeneration. Most importantly, recent studies have demonstrated the central role of glial cells in brain energy metabolism. A close and regulated metabolic conversation between neurons and both astrocytes and oligodendroglia in the central nervous system, or Schwann cells in the peripheral nervous system, has recently been shown to be an important determinant of the metabolism and function of the nervous system. This article reviews the current understanding of the long existing controversies regarding energy substrate and utilization in the nervous system and discusses the role of metabolic transporters in health and diseases of the nervous system.


Asunto(s)
Metabolismo Energético/fisiología , Transportadores de Ácidos Monocarboxílicos/metabolismo , Enfermedades del Sistema Nervioso/patología , Neuroglía/metabolismo , Neuronas/metabolismo , Animales , Humanos
15.
J Neurosci ; 24(36): 7945-50, 2004 Sep 08.
Artículo en Inglés | MEDLINE | ID: mdl-15356208

RESUMEN

Mutations in the Cu/Zn superoxide dismutase (SOD1) gene cause familial amyotrophic lateral sclerosis (FALS) by gain of an aberrant function that is not yet well understood. The role of Cu(2+) in mediating the toxicity of mutant SOD1 has been earnestly contested. We tested the in vivo effects of genetically induced copper deprivation on the ALS phenotype of transgenic mice expressing G86R mutant mouse SOD1, a protein that fails to incorporate Cu(2+) in its active site. Genetically copper-deficient SOD1(G86R) transgenic mice were produced by mating SOD1(G86R) males to female carriers of the X-linked mottled/brindled (Mobr) mutation. We found that the Mobr allele causes a severe ( approximately 60%) depletion of spinal cord copper levels; however, despite the burden of double genetic lesions, it lengthens the lives of SOD1(G86R) transgenic mice by 9%. These findings provide evidence supporting a role for copper in the pathogenesis of FALS linked to SOD1 mutations.


Asunto(s)
Adenosina Trifosfatasas/fisiología , Proteínas de Transporte de Catión/fisiología , Cobre/fisiología , Longevidad/genética , Proteínas del Tejido Nervioso/fisiología , Médula Espinal/química , Superóxido Dismutasa/fisiología , Adenosina Trifosfatasas/deficiencia , Adenosina Trifosfatasas/genética , Alelos , Sustitución de Aminoácidos , Esclerosis Amiotrófica Lateral/enzimología , Esclerosis Amiotrófica Lateral/genética , Animales , Sitios de Unión , Transporte Biológico Activo , Encéfalo/enzimología , Química Encefálica , Proteínas de Transporte de Catión/deficiencia , Proteínas de Transporte de Catión/genética , Cobre/análisis , ATPasas Transportadoras de Cobre , Cruzamientos Genéticos , Modelos Animales de Enfermedad , Inducción Enzimática , Femenino , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Mutantes , Ratones Transgénicos , Mutación Missense , Proteínas del Tejido Nervioso/deficiencia , Proteínas del Tejido Nervioso/genética , Fenotipo , Médula Espinal/enzimología , Médula Espinal/patología , Superóxido Dismutasa/deficiencia , Superóxido Dismutasa/genética , Superóxido Dismutasa-1
16.
Exp Neurol ; 263: 325-38, 2015 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-25447940

RESUMEN

Peripheral nerve regeneration following injury occurs spontaneously, but many of the processes require metabolic energy. The mechanism of energy supply to axons has not previously been determined. In the central nervous system, monocarboxylate transporter 1 (MCT1), expressed in oligodendroglia, is critical for supplying lactate or other energy metabolites to axons. In the current study, MCT1 is shown to localize within the peripheral nervous system to perineurial cells, dorsal root ganglion neurons, and Schwann cells by MCT1 immunofluorescence in wild-type mice and tdTomato fluorescence in MCT1 BAC reporter mice. To investigate whether MCT1 is necessary for peripheral nerve regeneration, sciatic nerves of MCT1 heterozygous null mice are crushed and peripheral nerve regeneration was quantified electrophysiologically and anatomically. Compound muscle action potential (CMAP) recovery is delayed from a median of 21 days in wild-type mice to greater than 38 days in MCT1 heterozygote null mice. In fact, half of the MCT1 heterozygote null mice have no recovery of CMAP at 42 days, while all of the wild-type mice recovered. In addition, muscle fibers remain 40% more atrophic and neuromuscular junctions 40% more denervated at 42 days post-crush in the MCT1 heterozygote null mice than wild-type mice. The delay in nerve regeneration is not only in motor axons, as the number of regenerated axons in the sural sensory nerve of MCT1 heterozygote null mice at 4 weeks and tibial mixed sensory and motor nerve at 3 weeks is also significantly reduced compared to wild-type mice. This delay in regeneration may be partly due to failed Schwann cell function, as there is reduced early phagocytosis of myelin debris and remyelination of axon segments. These data for the first time demonstrate that MCT1 is critical for regeneration of both sensory and motor axons in mice following sciatic nerve crush.


Asunto(s)
Transportadores de Ácidos Monocarboxílicos/metabolismo , Regeneración Nerviosa/fisiología , Nervio Ciático/metabolismo , Simportadores/metabolismo , Potenciales de Acción , Animales , Western Blotting , Técnica del Anticuerpo Fluorescente , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Microscopía Electrónica de Transmisión , Compresión Nerviosa , Reacción en Cadena en Tiempo Real de la Polimerasa , Nervio Ciático/lesiones
17.
Trends Cell Biol ; 23(12): 644-51, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-23988427

RESUMEN

Axons are specialized extensions of neurons that are critical for the organization of the nervous system. To maintain function in axons that often extend some distance from the cell body, specialized mechanisms of energy delivery are likely to be necessary. Over the past decade, greater understanding of human demyelinating diseases and the development of animal models have suggested that oligodendroglia are critical for maintaining the function of axons. In this review, we discuss evidence for the vulnerability of neurons to energy deprivation, the importance of oligodendrocytes for axon function and survival, and recent data suggesting that transfer of energy metabolites from oligodendroglia to axons through monocarboxylate transporter 1 (MCT1) may be critical for the survival of axons. This pathway has important implications both for the basic biology of the nervous system and for human neurological disease. New insights into the role of oligodendroglial biology provide an exciting opportunity for revisions in nervous system biology, understanding myelin-based disorders, and therapeutics development.


Asunto(s)
Axones/metabolismo , Oligodendroglía/metabolismo , Animales , Astrocitos/metabolismo , Transporte Biológico , Humanos , Ácido Láctico/metabolismo , Transportadores de Ácidos Monocarboxílicos/metabolismo , Simportadores/metabolismo
19.
Exp Neurol ; 217(2): 258-68, 2009 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-19285073

RESUMEN

Amyotrophic lateral sclerosis (ALS) is a neurologic disease characterized by progressive weakness that results in death within a few years of onset by respiratory failure. Myostatin is a member of the TGF-beta superfamily that is predominantly expressed in muscle and acts as a negative regulator of muscle growth. Attenuating myostatin has previously been shown to produce increased muscle mass and strength in normal and disease animal models. In this study, a mouse model of ALS (SOD1(G93A) transgenic mice) was treated with a soluble activin receptor, type IIB (ActRIIB.mFc) which is a putative endogenous signaling receptor for myostatin in addition to other ligands of the TGF-beta superfamily. ActRIIB.mFc treatment produces a delay in the onset of weakness, an increase in body weight and grip strength, and an enlargement of muscle size whether initiated pre-symptomatically or after symptom onset. Treatment with ActRIIB.mFc did not increase survival or neuromuscular junction innervation in SOD1(G93A) transgenic mice. Pharmacologic treatment with ActRIIB.mFc was superior in all measurements to genetic deletion of myostatin in SOD1(G93A) transgenic mice. The improved function of SOD1(G93A) transgenic mice following treatment with ActRIIB.mFc is encouraging for the development of TGF-beta pathway inhibitors to increase muscle strength in patients with ALS.


Asunto(s)
Receptores de Activinas Tipo II/uso terapéutico , Esclerosis Amiotrófica Lateral/tratamiento farmacológico , Debilidad Muscular/tratamiento farmacológico , Miostatina/antagonistas & inhibidores , Receptores de Activinas Tipo II/metabolismo , Esclerosis Amiotrófica Lateral/metabolismo , Esclerosis Amiotrófica Lateral/fisiopatología , Animales , Peso Corporal/efectos de los fármacos , Peso Corporal/fisiología , Células CHO , Cricetinae , Cricetulus , Modelos Animales de Enfermedad , Femenino , Masculino , Ratones , Ratones Transgénicos , Fuerza Muscular/efectos de los fármacos , Fuerza Muscular/fisiología , Debilidad Muscular/etiología , Debilidad Muscular/fisiopatología , Músculo Esquelético/efectos de los fármacos , Músculo Esquelético/metabolismo , Miostatina/metabolismo , Proteínas Recombinantes de Fusión/síntesis química , Proteínas Recombinantes de Fusión/uso terapéutico , Superóxido Dismutasa/genética , Superóxido Dismutasa-1 , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA